Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Autonomous & Electric Vehicles (DRIV) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Global X Autonomous & Electric VehiclesTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Global X Autonomous & Electric Vehicles vs Regeneron Pharmaceuticals Inc — how do they compare? Global X Autonomous & Electric Vehicles trades at $35.42, while Regeneron Pharmaceuticals Inc trades at $796.32 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Global X Autonomous & Electric Vehicles pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Global X Autonomous & Electric Vehicles nearer its low. Which is the better fit depends on your goals.

DRIVREGN
Sector
Sector/ThematicHealth
52-Week High
$42.53$812.27
52-Week Low
$25.23$555.51
Market Cap
$83.19B
Enterprise Value
$77.90B
Dividend Yield
0.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Autonomous & Electric Vehicles

DRIV trades at $35.78, up 2.55% today, with a bullish technical signal driven by moving averages. The stock shows strong year-to-date performance, supported by positive sentiment in the electric vehicle sector. Key support is at $35, with resistance at $36. Recent news highlights global EV sales growth and China's expanding market ambitions.

Outlook remains positive due to sector tailwinds and autonomous driving advancements, but risks include regulatory pressures and competitive threats from Chinese automakers. Institutional interest is strong, though overbought RSI signals caution near-term.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.

Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X Autonomous & Electric Vehicles

DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.

Read more on DRIV

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN